BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma

Inclusion Criteria: * KPS 60% * Histological confirmation of urothelial carcinoma , with metastatic disease * Measurable disease * Previously treated with platinum-based chemotherapy administered Exclusion Criteria: * Radiographic evidence of cavitary or necrotic tumours * Active brain metastasis.Leptomeningeal metastasis * Chemotherapy, radiotherapy, targeted therapy with monoclonal antibodies or small tyrosine kinase inhibitors * Grade 1 treatment-related toxicity from previous chemotherapy, radiotherapy, or targeted therapy * Prior treatment with BIBF 1120 or other VEGFR inhibitors * Significant cardiovascular diseases: * Pericardial effusion * Significant bleeding or thrombosis * Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug * Major injuries within the past 10 days with incomplete wound healing and/or planned surgery during the on-treatment study period